R.H. Bluestein & Co’s Vanguard FTSE Developed Markets ETF VEA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$1.35M Sell
37,039
-3,525
-9% -$144K 0.08% 76
2022
Q2
$1.66M Buy
40,564
+8,204
+25% +$365K 0.1% 74
2022
Q1
$1.55M Buy
32,360
+2,240
+7% +$109K 0.07% 77
2021
Q4
$1.54M Buy
30,120
+11,325
+60% +$581K 0.06% 81
2021
Q3
$949K Buy
18,795
+9,135
+95% +$475K 0.04% 121
2021
Q2
$498K Buy
9,660
+4,000
+71% +$206K 0.02% 226
2021
Q1
$278K Buy
5,660
+100
+2% +$4.88K 0.01% 331
2020
Q4
$262K Buy
+5,560
New +$245K 0.01% 314
2020
Q3
Sell
-5,560
Closed -$216K 369
2020
Q2
$216K Sell
5,560
-8,270
-60% -$302K 0.01% 301
2020
Q1
$461K Sell
13,830
-4,190
-23% -$168K 0.04% 126
2019
Q4
$794K Buy
18,020
+3,615
+25% +$154K 0.04% 105
2019
Q3
$592K Buy
+14,405
New +$588K 0.03% 129

Other funds holding VEA

R.H. Bluestein & Co's VEA Position: Q3 2022 in Review

R.H. Bluestein & Co reduced its Vanguard FTSE Developed Markets ETF (VEA) stake by 8.7% in Q3 2022, selling an estimated $144K and leaving 37,039 shares worth $1.35M. The position accounts for 0.08% of the portfolio, ranked #76.

R.H. Bluestein & Co first reported a position in VEA in Q3 2019 and has held it in 12 quarters since. The position peaked at $1.66M in Q2 2022. 1,719 funds tracked by Wall St. Rank hold VEA as of Q3 2022.

  • R.H. Bluestein & Co held 37,039 shares of Vanguard FTSE Developed Markets ETF worth $1.35M as of Q3 2022.
  • R.H. Bluestein & Co sold 3,525 Vanguard FTSE Developed Markets ETF shares in Q3 2022, an estimated $144K.
  • Vanguard FTSE Developed Markets ETF made up 0.08% of R.H. Bluestein & Co's portfolio in Q3 2022, its #76 holding.
  • R.H. Bluestein & Co first reported a position in Vanguard FTSE Developed Markets ETF in Q3 2019 and has held it in 12 quarters since.
  • R.H. Bluestein & Co's Vanguard FTSE Developed Markets ETF position peaked at $1.66M in Q2 2022.
  • 1,719 funds tracked by Wall St. Rank held Vanguard FTSE Developed Markets ETF as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.